Media coverage
1
Media coverage
Title FDA APPROVES G1 THERAPEUTICS’ COSELA™ (TRILACICLIB): THE FIRST AND ONLY MYELOPROTECTION THERAPY TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION Media name/outlet Hatteras Venture Partners Country/Territory United States Date 18/02/21 URL hatterasvp.com/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/ Persons William Roberts